# [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Source: https://nuclide.cc/trials/nct05936658/  
Nuclide record `nct05936658` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Florastamin F-18 run by FutureChem, active.

## Summary

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT05936658 by FutureChem, with 138 participants enrolled, started 2023-05-08. Conditions listed: High Risk Prostate Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05936658
- Phase: 3
- Setting: A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
- Sponsor: FutureChem
- Enrolled: 138

## Sources

- ClinicalTrials.gov NCT05936658: https://clinicaltrials.gov/study/NCT05936658

## Connected records

- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/)
- indications: [Prostate cancer](https://nuclide.cc/indications/prostate/)
- drugs: [Florastamin F-18](https://nuclide.cc/drugs/florastamin-f18/)
- companies: [FutureChem](https://nuclide.cc/companies/futurechem/)

---
JSON: https://nuclide.cc/api/v1/entities/nct05936658.json